Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P4JE | ISIN: US74365U1079 | Ticker-Symbol: 1KPA
Stuttgart
06.06.25 | 08:01
2,680 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PROTARA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PROTARA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,8802,98006.06.
2,8802,98006.06.

Aktuelle News zur PROTARA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoProtara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer104NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...
► Artikel lesen
08.05.Protara Therapeutics, Inc. - 10-Q, Quarterly Report15
08.05.Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update125Reported positive interim results demonstrating durable responses in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC Results from planned interim analysis of approximately 25 six-month evaluable...
► Artikel lesen
08.05.Protara Therapeutics, Inc. - 8-K, Current Report-
PROTARA THERAPEUTICS Aktie jetzt für 0€ handeln
28.04.Protara Therapeutics stock drops following interim trial results7
28.04.Protara Therapeutics-Aktie fällt nach vorläufigen Studienergebnissen23
28.04.Protara Therapeutics, Inc. - 8-K, Current Report1
26.04.Protara Therapeutics Shares Positive Phase 2 Interim Results Of TARA-002 In Patients With NMIBC4
26.04.Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC108TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patientsTARA-002 demonstrates 76% complete response rate at any time...
► Artikel lesen
15.04.Protara Therapeutics appoints Leonardo Nicacio as chief medical officer13
15.04.Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer95NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
► Artikel lesen
10.04.Protara to present bladder cancer trial data at AUA meeting10
10.04.Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting1
19.03.Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support2
14.03.Cantor Fitzgerald sets Overweight rating on Protara stock3
06.03.H.C. Wainwright maintains Buy rating on Protara stock, $23 target1
05.03.Protara Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
05.03.Protara Therapeutics reports Q4 results2
05.03.Protara Therapeutics, Inc. Q4 Loss Beats Estimates2
05.03.Protara Therapeutics, Inc. - 10-K, Annual Report-
Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1